Latest Breaking News On - நீரிழிவு புற நரம்பியல் - Page 1 : comparemela.com
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
ACCESSWIRE
SON-1010, fully-human IL-12 configured using F
HAB platform, advancing towards IND submission
At-The-Market offering program resulted in net proceeds of $10.2 million
PRINCETON, NJ / ACCESSWIRE / May 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ( Sonnet or the Company ), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended March 31, 2021 and provided a business update. Over the course of the quarter, we have made several advancements across our pipeline products, most notably of which are the completion of non-human primate (NHP) toxicology study of SON-080 and the completion of a repeat dose study of SON-1010 in NHPs, commented Pankaj Mohan, Ph.D., Founder and CEO. Additionally, we were thrilled to have our abstract detailing data from our NHP study of SON-1010 accep
United-states
American
Jay-cross
Pankaj-mohan
Richard-kenney
Jalan-lada
Exchange-commission
American-association-for-cancer-research
Sonnet-biotherapeutics-inc
Securities-exchange
Sonnet-biotherapeutics-holdings-inc
Nasdaq
(PDN) is the most common complication of both type 1 and 2 diabetes and occurs in more than half of affected individuals in both hospital and clinic settings.
According to DelveInsight s estimates, the total prevalent cases of selected indications for Chronic Pain associated with Painful Diabetic Neuropathy were
7,670,318 cases in the 7MM in
2018 and are expected to get increased by
2030. The 3,782,136 cases in the same year.
Looking forward to the
Medical device technology market for PDN, two technologies are available in the Chronic Pain associated with Painful Diabetic Neuropathy market approved over the years by the
FDA and
EMA.
Transcutaneous electrical stimulation (TENS) is one low-cost option that patients can administer at home and used as a Diabetic Peripheral Neuropathy treatment.
Germany
Italy
Japan
United-kingdom
France
Spain
Shruti-thakur
Daiichi-sankyo
Prnewswire-delveinsight
Eli-lilly
Pfizer
Regenacy-pharmaceuticals
vimarsana © 2020. All Rights Reserved.